Monday, April 22, 2019

Avidity Biosciences Lands $35M In Deal With Lilly

La Jolla-based Avidity Biosciences, a developer of biopharmaceuticals that uses monoclonal antibodies and oligonucleotide-based therapeutics, said on Monday that it has received $20M in an upfront payment, as well as an investment of $15M in a deal with Lilly. According to Avidity, the company is also

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.